Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Hoth Therapeutics Inc (HOTH)

Hoth Therapeutics Inc (HOTH)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.8556 -0.0031 (-0.36%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 0.8554 -0.0002 (-0.02%) 19:59 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.8259
Day High
0.8655
Open 0.8655
Previous Close 0.8587 0.8587
Volume 83,900 83,900
Avg Vol 626,310 626,310
Stochastic %K 77.52% 77.52%
Weighted Alpha -73.71 -73.71
5-Day Change +0.0680 (+8.63%) +0.0680 (+8.63%)
52-Week Range 0.5800 - 3.8000 0.5800 - 3.8000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,310
  • Shares Outstanding, K 13,171
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,190 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta 0.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.97
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.33
  • Most Recent Earnings $-0.32 on 03/28/25
  • Next Earnings Date 05/13/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.34
  • Number of Estimates 1
  • High Estimate -0.34
  • Low Estimate -0.34
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +26.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6600 +29.64%
on 04/08/25
Period Open: 1.0400
1.0600 -19.28%
on 03/26/25
-0.1844 (-17.73%)
since 03/25/25
3-Month
0.6600 +29.64%
on 04/08/25
Period Open: 1.3600
1.3500 -36.62%
on 01/31/25
-0.5044 (-37.09%)
since 01/24/25
52-Week
0.5800 +47.52%
on 08/08/24
Period Open: 1.1700
3.8000 -77.48%
on 01/07/25
-0.3144 (-26.87%)
since 04/25/24

Most Recent Stories

More News
The Trump Effect: Crypto Diversification Accelerates Across Industries

Issued on behalf of Spearmint Resources Inc. VANCOUVER – USA News Group – With the upcoming inauguration of US President Re-Elect Donald Trump on the horizon, several businesses are diversifying...

MSTR : 368.71 (+5.24%)
TSLA : 284.95 (+9.80%)
ENLV : 0.9845 (+2.55%)
SPMTF : 0.0108 (+4.85%)
SPMT.CN : 0.0200 (+33.33%)
^BTCUSDT : 94,709.99 (-0.13%)
HOTH : 0.8556 (-0.36%)
^BTCUSD : 94,855.32 (-0.10%)
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal

Shares of Hoth Therapeutics HOTH skyrocketed 178.2% on Tuesday after the company announced positive interim safety and efficacy results from a mid-stage study of its lead candidate, HT-001, which is being...

CTMX : 0.7100 (-7.29%)
CSTL : 20.63 (-1.43%)
HOTH : 0.8556 (-0.36%)
HALO : 60.49 (+2.09%)
Hoth Therapeutics’ Stock Triples On Promising Cancer Trial Data for Skin Toxicity Therapy: Retail’s Excited

The trial achieved a 100% success rate for its primary efficacy endpoint, with all patients showing significant improvement in skin toxicities within six weeks.

HOTH : 0.8556 (-0.36%)
Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced, its initiative to utilize Artificial...

HOTH : 0.8556 (-0.36%)
FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the Pre-IND meeting requested on September...

HOTH : 0.8556 (-0.36%)
Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) ("Hoth" or the "Company"), a patient-focused biopharmaceutical company, today announced the closing of...

HOTH : 0.8556 (-0.36%)
Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive...

HOTH : 0.8556 (-0.36%)
Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that HT-KIT, a new molecular entity, for...

HOTH : 0.8556 (-0.36%)
Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has submitted a request for a...

HOTH : 0.8556 (-0.36%)
Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa

/PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has completed its analysis of the...

HOTH : 0.8556 (-0.36%)

Business Summary

Hoth Therapeutics Inc. is a development stage biopharmaceutical company. It focused on therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. The company's BioLexa(TM) Platform is a proprietary, patented drug compound platform. Hoth Therapeutics Inc. is...

See More

Key Turning Points

3rd Resistance Point 0.9117
2nd Resistance Point 0.8886
1st Resistance Point 0.8721
Last Price 0.8556
1st Support Level 0.8325
2nd Support Level 0.8094
3rd Support Level 0.7929

See More

52-Week High 3.8000
Fibonacci 61.8% 2.5700
Fibonacci 50% 2.1900
Fibonacci 38.2% 1.8100
Last Price 0.8556
52-Week Low 0.5800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective